WO2010024325A1 - 血液採取容器 - Google Patents
血液採取容器 Download PDFInfo
- Publication number
- WO2010024325A1 WO2010024325A1 PCT/JP2009/064947 JP2009064947W WO2010024325A1 WO 2010024325 A1 WO2010024325 A1 WO 2010024325A1 JP 2009064947 W JP2009064947 W JP 2009064947W WO 2010024325 A1 WO2010024325 A1 WO 2010024325A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- blood collection
- collection container
- coagulation promoter
- antifoaming agent
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/15003—Source of blood for venous or arterial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150351—Caps, stoppers or lids for sealing or closing a blood collection vessel or container, e.g. a test-tube or syringe barrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
- A61B5/154—Devices using pre-evacuated means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/16—Surface properties and coatings
- B01L2300/161—Control and use of surface tension forces, e.g. hydrophobic, hydrophilic
- B01L2300/163—Biocompatibility
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5082—Test tubes per se
Definitions
- the present invention relates to a blood collection container used for clinical tests such as serum biochemical tests and serum immunology tests.
- Blood tests are widely performed for the purpose of disease prevention and diagnosis. Many of the blood tests are serum tests such as serum biochemical tests, serum immunology tests, serum endocrine substance tests, serum tumor marker tests, and serum drug concentration tests.
- blood collection containers such as vacuum blood collection tubes and blood collection tubes are widely used to collect serum from blood. Blood is collected in a blood collection container, and after the collected blood is coagulated, serum is separated from clots having different specific gravity by centrifugation, and the serum is taken out.
- a glass container or a container made of synthetic resin such as polystyrene, polymethyl methacrylate, polyethylene, polyethylene terephthalate or the like is used.
- synthetic resin such as polystyrene, polymethyl methacrylate, polyethylene, polyethylene terephthalate or the like.
- a glass blood collection container When a glass blood collection container is used, blood can be coagulated in a relatively short time, but it took about 40 to 60 minutes for the blood to coagulate.
- blood test containers made of synthetic resin were used, it took more than 4 hours for blood to clot. Therefore, in order to coagulate blood in a shorter time, a blood coagulation promoter that promotes blood coagulation is used.
- Blood clotting is known to occur by multiple pathways that begin with the activation of blood clotting factor XII and then go through a number of reaction stages and eventually end when fibrinogen is converted to fibrin. ing.
- an enzyme drug such as thrombin or snake venom enzyme that promotes a reaction in which fibrinogen, which is the final stage of blood coagulation, is converted to fibrin is used as a blood coagulation promoter that promotes blood coagulation. It has been.
- these enzyme drugs as blood coagulation promoters, blood can be coagulated within 5 minutes.
- the object of the present invention is to allow the blood to coagulate in a short time and to coagulate the blood in a state containing bubbles when the blood is collected in the blood collection container.
- An object of the present invention is to provide a blood collection container that can suppress the formation of a blood clot.
- a blood coagulation promoter and an antifoaming agent that is polyoxyalkylene or a derivative thereof are accommodated, and the amount of the antifoaming agent is 2 per 1 mL of blood collected in a blood collection container.
- a blood collection container is provided, characterized in that it is in the range of 0.0 ⁇ 10 ⁇ 3 to 0.2 mg.
- a water-soluble binder is further contained in the blood collection container.
- the blood coagulation promoter or antifoaming agent adheres more uniformly to the inner surface of the blood collection container, and peeling of the blood coagulation promoter or antifoaming agent from the inner surface of the blood collection container is also suppressed. After blood has flowed into it, when it comes into contact with the blood by mixing, it quickly dissolves, and the blood coagulation promoter can be uniformly dispersed in the blood.
- the water-soluble binder is preferably at least one selected from the group consisting of polyvinyl alcohol, polyvinyl pyrrolidone, acrylic acid copolymers and polyoxyalkylene block copolymers. When these water-soluble binders are used, peeling of the blood coagulation promoter or antifoaming agent from the inner surface of the blood sampling container is less likely to occur.
- the defoaming is performed so that the first height position above the liquid level of the blood collected in the blood collection container reaches the second height position below. Agent is placed.
- the blood comes into contact with the antifoaming agent, so that even if bubbles are generated, the bubbles disappear quickly.
- a tubular container having an opening at one end and a stopper attached airtight to the opening are provided.
- the antifoaming agent is applied to substantially the entire inner surface of the tubular container, whereby the bubbles disappear more effectively.
- the blood coagulation promoter contained in the blood collection container preferably contains a serine protease.
- serine protease When serine protease is included, blood coagulation efficiency is further enhanced.
- the blood flow directly hits the bottom inside the blood collection container, so that the serine protease is accommodated in a position not in direct contact with the blood flow. Yes. Therefore, almost simultaneously with blood collection, serine protease and blood are not in contact with each other, and blood coagulation proceeds immediately after blood collection, so blood does not coagulate and does not contain air bubbles when it contains air bubbles. The blood coagulation efficiency is further increased.
- the serine protease is preferably spray-coated on the inner surface of the blood collection container.
- the serine protease is spray-applied, blood is rapidly coagulated when the collected blood is brought into contact with serine protease.
- the blood coagulation promoter preferably contains an adsorptive inorganic substance.
- an adsorptive inorganic substance blood in contact with the blood coagulation promoter coagulates more rapidly.
- the first height position above the liquid level of the blood collected in the blood collection container reaches the second height position below.
- the adsorptive inorganic substance is disposed. In this case, when blood is collected in the blood collection container, the blood comes into contact with the adsorptive inorganic substance, so that the blood coagulates uniformly in a shorter time.
- the adsorptive inorganic substance is applied to substantially the entire inner surface of the tubular container, whereby blood is coagulated uniformly in a shorter time.
- the blood collection container according to the present invention is preferably a vacuum blood collection tube having a reduced pressure inside. In this case, a predetermined amount of blood can be collected easily.
- the blood coagulation promoter since the blood coagulation promoter is housed in the blood collection container, the blood can be coagulated in a short time. Furthermore, since the antifoaming agent which is the specific amount of polyoxyalkylene or a derivative thereof is contained in the blood collection container, when blood is collected in the blood collection container, the blood is faster than the blood clots, Air bubbles are completely eliminated by the antifoaming agent. Therefore, blood is difficult to coagulate in a state containing bubbles, and a foamy clot is difficult to be generated. Therefore, it is possible to suppress red blood cells from being mixed into the serum during centrifugation. Furthermore, collection of the separated serum is difficult to be inhibited by the foamy clot after centrifugation.
- FIGS. 1A and 1B are an external perspective view and a front sectional view showing a blood collection container according to an embodiment of the present invention.
- FIG. 1 (a) and 1 (b) show an external perspective view and a front sectional view of a blood collection container according to an embodiment of the present invention.
- a blood collection container 1 from which blood is collected includes a tubular container 2 and a stopper 3.
- the tubular container 2 has an opening 2a at one end and a bottom 2b at the other end opposite to the one end.
- the plug 3 has a large diameter portion 3a and a small diameter portion 3b having a smaller diameter than the large diameter portion 3a.
- the small diameter portion 3b of the plug body 3 is press-fitted into the opening 2a of the tubular container 2, and the plug body 3 is attached in an airtight and liquid tight manner.
- thermoplastic resins such as polyethylene, polypropylene, polystyrene, polyethylene terephthalate, polymethyl methacrylate, and polyacrylonitrile
- thermosetting resins such as unsaturated polyester resins, epoxy resins, and epoxy-acrylate resins
- Modified natural resins such as cellulose, cellulose propionate, ethyl cellulose and ethyl chitin
- silicate glass such as soda lime glass, phosphosilicate glass and borosilicate glass, glass such as quartz glass, and those mainly composed of these Used.
- the plug 3 is made of a material and a shape that can be airtight and liquid tightly attached to the opening 2 a of the tubular container 2. It is preferable that the stopper 3 is configured so that a blood collection needle can be pierced.
- the plug body 3 in addition to a rubber plug body having a shape that fits into the opening 2a, when the plug body 3 is pulled out from the opening 2a after blood collection, it is made of plastic or the like that makes it difficult for blood to come into contact with the human body. Examples thereof include a rubber plug whose surface is covered and a sheet-like sealing member.
- Examples of the material of the plug 3 include synthetic resin, elastomer, rubber such as butyl rubber and halogenated butyl rubber, and metal foil such as aluminum foil. Of these, butyl rubber is preferable because the sealing performance is improved.
- a blood coagulation promoter-containing composition 4 and an antifoaming agent-containing composition 5 are accommodated.
- the blood coagulation promoter-containing composition 4 contains a blood coagulation promoter (A) described later.
- the antifoamer-containing composition 5 includes a blood coagulation promoter (B) described later and an antifoamer that is polyoxyalkylene or a derivative thereof. Therefore, the blood collection container 1 contains a blood coagulation promoter (A), a blood coagulation promoter (B), and an antifoaming agent that is polyoxyalkylene or a derivative thereof.
- the blood coagulation promoter-containing composition 4 is contained in a position where it does not come into direct contact with blood flow when blood is collected in the blood collection container 1. Therefore, the housing position of the blood coagulation promoter-containing composition 4 is preferably within a region of 7 mm to 50 mm from the opening of the tubular container 2, more preferably within a region of 7 mm to 40 mm, and even more preferably within a region of 7 mm to 30 mm. . Therefore, after blood collection, for example, in a state where the blood collection container 1 is upright, it is difficult for blood to come into contact with the blood coagulation promoter (A). It is suppressed that the blood coagulates in the containing state.
- the blood coagulation promoter-containing composition 4 is spray-applied to the inner surface 2c of the tubular container 2 and adhered substantially uniformly to the inner surface 2c of the tubular container 2. Since it can adhere more uniformly by the inner surface 2c of the tubular container 2, the blood coagulation promoter-containing composition 4 containing the blood coagulation promoter (A) is preferably spray-coated.
- the spray coating method uses a double-tube structure spray nozzle and sprays two fluids of air and drug solution as an aerosol by the pressure of compressed gas, or one or more fine through-holes with a single tube structure. And a method of spraying liquid droplets by applying a compressed gas pressure to the drug solution.
- the antifoam-containing composition 5 is arranged so as to reach from the first height position above the liquid level of the blood collected in the blood collection container 1 to the second height position below. ing. That is, the antifoam-containing composition 5 is accommodated so that blood is collected in the blood collection container 1 so as to come into contact with the blood. Therefore, since blood contacts the antifoaming agent after blood collection, even if bubbles are generated, the bubbles can be quickly removed.
- the antifoam-containing composition 5 is spray-applied to substantially the entire inner surface 2c of the tubular container 2, and is applied substantially uniformly to the substantially entire inner surface 2c of the tubular container 2.
- the blood coagulation promoter (B) such as an adsorptive inorganic substance and the antifoaming agent which is polyoxyalkylene or a derivative thereof are provided on substantially the entire inner surface 2 c of the tubular container 2.
- the substantially entire surface of the inner surface 2c of the tubular container 2 refers to the region of the portion where the plug 3b attached to the opening 2a of the tubular container 2 is in contact with the inner wall surface 2c of the tubular container 2. The case where it is not included shall be included.
- the anticoagulant-containing composition 5 is applied to the inner surface 2c of the tubular container 2, and then the blood coagulation promoter-containing composition 4 is applied. Before the antifoamer-containing composition 5 is applied, the blood coagulation promoter-containing composition 4 may be applied.
- the blood coagulation promoter (A) contained in the composition 4 containing blood coagulation promoter contains a bond between arginine of peptide chain and any amino acid residue and / or a bond between lysine and any amino acid residue. It is a hydrolase that can be hydrolyzed.
- the blood coagulation promoter (A) include, for example, serine proteases such as trypsin, thrombin and snake venom thrombin-like enzymes; thiol proteases such as cathepsin B and ficin; hydrolysis of metal proteases such as kininase I and the like. Enzymes. Especially, since the coagulation efficiency of blood is improved, serine protease is preferable as the blood coagulation promoter (A), and thrombin is preferable as the serine protease.
- the amount of the blood coagulation promoter (A) accommodated in the blood collection container 1 is preferably 0.5 to 50 units, more preferably 1 to 20 units, per 1 mL of blood after collection.
- the blood coagulation promoter-containing composition 4 preferably contains a blood coagulation promoter (A) stabilizer.
- the blood collection container 1 preferably contains a stabilizer.
- the stabilizer for example, an enzyme inactivated product obtained by inactivating the hydrolase as a blood coagulation promoter (A) by irradiation and ⁇ -alanine are used. Examples of the radiation in radiation irradiation include gamma rays and electron beams. Enzyme inactivated materials may be used alone or in combination of two or more.
- the amount of the enzyme deactivator accommodated in the blood collection container 1 is preferably 0.001 to 100 ⁇ g, more preferably 0.01 to 10 ⁇ g, and still more preferably, per unit of the blood coagulation promoter (A). 0.03 to 5 ⁇ g. If there are too few enzyme deactivation substances, the hydrolase may not be sufficiently stabilized, and if it is too much, it will be disadvantageous in production cost.
- the amount of the enzyme deactivator is preferably the minimum necessary amount that can achieve the desired performance.
- the enzyme-inactivated substance As the method for adding the enzyme-inactivated substance, it may be added as an enzyme-inactivated substance after being deactivated by irradiation, and after adding the active hydrolase, the hydrolase is irradiated with radiation. By irradiating, a part of the hydrolase may be inactivated to obtain an enzyme inactivated product.
- the amount of ⁇ -alanine accommodated in the blood collection container 1 is preferably 0.01 to 1000 ⁇ g, more preferably 0.1 to 200 ⁇ g, most preferably, per unit of the blood coagulation promoter (A). 0.5 to 50 ⁇ g. If the amount of ⁇ -alanine is too small, the hydrolase may not be sufficiently stabilized. If the amount is too large, ⁇ -alanine is not sufficiently dissolved in the solution containing the hydrolase, and a blood coagulation promoter is contained. Ingredients in the composition 4 may become non-uniform, and spray coating of the blood coagulation promoter-containing composition 4 may be difficult.
- the amount of ⁇ -alanine is preferably an amount that can be uniformly dissolved in the hydrolase.
- the antifoaming agent contained in the antifoaming agent-containing composition 5 is polyoxyalkylene or a derivative thereof. Although it does not specifically limit as polyoxyalkylene or its derivative (s), A substance with low solubility to water and high dispersibility is used suitably.
- polyoxyalkylene ether is preferable because of its excellent defoaming effect.
- examples of the polyoxyalkylene ether include polyoxypropylene, polyoxypropylene glyceryl ether, polyoxyethylene, polyoxyethylene glyceryl ether, poly (oxyethylene oxypropylene), poly (oxyethylene oxypropylene) glyceryl ether, and the like. Can be mentioned.
- the amount of antifoam contained in the blood collection container 1 is in the range of 2.0 ⁇ 10 ⁇ 3 to 0.2 mg per 1 ml of collected blood. If the amount of the antifoaming agent is too small, the antifoaming effect may not be sufficiently obtained. If the amount is too large, insoluble matter remains, and when blood is collected during a clinical test, it is used as a sample collecting nozzle. Insoluble materials are likely to be clogged, which may cause problems in clinical examinations. Therefore, the amount of the antifoaming agent accommodated in the blood collection container 1 is preferably in the range of 3.0 ⁇ 10 ⁇ 3 to 0.11 mg per 1 mL of collected blood.
- the blood coagulation promoter (B) contained in the antifoam-containing composition 5 is an adsorptive substance.
- the antifoam-containing composition 5 preferably contains a blood coagulation promoter (B) that is an adsorbent substance.
- the blood collection container 1 preferably contains a blood coagulation promoter (B) that is an adsorptive substance.
- the adsorptive substance examples include silica, glass, kaolin, celite, bentonite and the like. Since the adsorptive inorganic substance has a large specific surface area, the blood can be uniformly coagulated in a shorter time by bringing the blood into contact with the blood coagulation promoter (B), which is the adsorptive inorganic substance. Since blood can be coagulated uniformly in a shorter time, the blood coagulation promoter (B) is preferably in the form of a powder having a large specific surface area.
- the amount of the blood coagulation promoter (B) stored in the blood collection container 1 is preferably 1 ⁇ 10 ⁇ 6 to 1 ⁇ 10 ⁇ 2 g per 1 mL of blood after collection, and 1 ⁇ 10 ⁇ 5 to 1 ⁇ 10 ⁇ 3 g is more preferable.
- Both the blood coagulation promoter-containing composition 4 and the antifoaming agent-containing composition 5 preferably contain a water-soluble binder.
- the blood collection container 1 preferably contains a water-soluble binder.
- a blood coagulation promoter or antifoaming agent adheres more evenly to the inner surface of the blood collection container 1 and from the inner surface of the blood collection container 1 of the blood coagulation promoter or antifoaming agent. Is also prevented from peeling. Further, after the blood has flowed in, when it comes into contact with the blood by mixing, it dissolves quickly, and the blood coagulation promoter is uniformly dispersed in the blood.
- the water-soluble binder is not particularly limited as long as it is a compound that does not affect the inspection, but for example, polyvinyl alcohol, polyvinyl pyrrolidone, acrylic acid copolymer, polyoxyalkylene block copolymer and the like are suitable. Among these, polyvinyl pyrrolidone is more preferable because the blood coagulation promoter and the antifoaming agent are more difficult to peel from the inner surface of the blood collection container 1.
- the weight average molecular weight of the polyvinyl pyrrolidone is preferably 1 to 600,000, more preferably 3 to 500,000. If the weight average molecular weight is too small, hemolysis is likely to occur. If the weight average molecular weight is too large, solubility in blood is insufficient and the action of the hydrolase may be inhibited.
- the amount of the water-soluble binder added to the antifoam-containing composition 5 contained in the blood collection container 1 is preferably 1 ⁇ 10 ⁇ 4 to 2 mg per 1 ml of collected blood, and 1 ⁇ 10 ⁇ 3. ⁇ 1 mg is more preferred.
- a serum separating agent 6 is accommodated in the bottom 2b of the blood collection container 1.
- the blood separating container 6 contains the serum separating agent 6.
- the serum separating agent 6 moves between the clot and the serum during centrifugation, and a partition is formed, so that the serum is effectively separated. Is done.
- the serum separating agent 6 is a gel-like substance having thixotropic properties.
- an additive such as a thixotropic property imparting agent, a specific gravity adjusting agent, a compatibilizing agent, or a viscosity adjusting agent is added to a synthetic resin having fluidity at room temperature. Is added and mixed.
- a plasticizer such as a thixotropy imparting agent, a specific gravity regulator, a compatibilizer, or a viscosity modifier.
- Examples of the synthetic resin include dicyclopentadiene oligomers.
- Examples of the thixotropic property-imparting agent include condensates of sorbitol and aromatic aldehyde, polyoxyethylene polyoxyalkylene block copolymers, and the like.
- Examples of the specific gravity adjusting agent include silica.
- Examples of the viscosity modifier and the plasticizer include phthalic acid esters and trimellitic acid esters.
- Examples of the compatibilizing agent include partially hydrogenated triphenyl.
- the antifoaming agent is mixed with the blood coagulation promoter (B) and stored, but the blood coagulation promoter (B) and the antifoaming agent are separated by being carried on a carrier, respectively. May be. Further, the antifoaming agent may be added to the blood coagulation promoter-containing composition 4 and mixed with the blood coagulation promoter (A). The blood coagulation promoter and the antifoaming agent may be accommodated in the blood collection container 1 so as to be mixed at the time of use.
- all components contained in the blood collection container 1 or an aqueous solution or aqueous dispersion of each component are applied by spraying, or the carrier is supported by immersing the carrier in the aqueous solution or aqueous dispersion. Methods and the like.
- the blood coagulation promoter containing composition 4 and the antifoaming agent containing composition 5 are each spray-applied to the inner surface 2c of the tubular container 2, It is obtained by airtightly attaching the plug 3 to the opening 2a of the tubular container 2.
- the inside of blood collection container 1 is preferably decompressed. In this case, the blood collection container 1 can be used as a vacuum blood collection tube.
- Blood coagulation promoter (A): Thrombin (trade name: Thrombin Ito, manufactured by Ito Pharmaceutical Co., Ltd.) Blood coagulation promoter (B): Silica (made by UNIMIN SPECIALTY MINALAL) Antifoam: Polyoxypropylene glyceryl ether (Adeka Polyether G-4000, manufactured by Adeka) Poly (oxyethylene oxypropylene) glyceryl ether (Adeka Polyether AM-502, manufactured by Adeka) Polyoxypropylene ether (Adeka Polyether P-3000, manufactured by Adeka) Water-soluble binder: Polyvinylpyrrolidone (PVP-K30, manufactured by Wako Pure Chemical Industries, Ltd.) Tubular container: Polyethylene terephthalate tubular container (internal volume 7.8 mL, inner diameter 10.8 mm ⁇ length 100 mm, manufactured by Sekisui Chemical Co., Ltd.) Serum separating agent: thixotropic separating agent (manu
- Example 1 The bottom of the tubular container was filled with 0.8 mL of a thixotropic separating agent as a serum separating agent.
- thrombin as a blood coagulation promoter (A) was dissolved in 0.008 mg of polyvinylpyrrolidone as a water-soluble binder per mL of blood to obtain a blood coagulation promoter-containing composition.
- the obtained blood coagulation promoter-containing composition was spray-applied uniformly to the inner surface of the tubular container in an area of 7 to 30 mm from the opening of the tubular container so that the thrombin amount was 9.5 units per mL of blood. .
- the stopper was airtightly attached to the opening of the tubular container, and the inside was depressurized so that the amount of blood collected was 5 mL, whereby a vacuum blood collection tube was obtained.
- Example 2 to 15 A vacuum blood collection tube was obtained in the same manner as in Example 1 except that the type of the antifoaming agent and the blending amount thereof were changed as shown in Table 1 below.
- Example 16 to 19 A vacuum blood collection tube was obtained in the same manner as in Example 4 except that the amount of the water-soluble binder in the antifoamer-containing composition was changed as shown in Table 1 below.
- Example 20 to 23 A vacuum blood collection tube was obtained in the same manner as in Example 4 except that the blending amount of the blood coagulation promoter (A) was changed as shown in Table 1 below.
- Example 24 A vacuum blood collection tube was obtained in the same manner as in Example 4 except that the blood coagulation promoter-containing composition was sprayed uniformly over the entire inner surface of the tubular container.
- Example 25 A vacuum blood collection tube was obtained in the same manner as in Example 24 except that the type of antifoaming agent was changed as shown in Table 1 below.
- Example 27 A vacuum blood collection tube was obtained in the same manner as in Example 4 except that no water-soluble binder was added to the antifoamer-containing composition.
- Example 28 A vacuum blood collection tube was obtained in the same manner as in Example 4 except that the amount of the water-soluble binder in the antifoamer-containing composition was changed as shown in Table 1 below.
- Example 29 and 30 A vacuum blood collection tube was obtained in the same manner as in Example 4 except that the blending amount of the blood coagulation promoter (A) was changed as shown in Table 1 below.
- Example 31 A vacuum blood collection tube was obtained in the same manner as in Example 4 except that the blood coagulation promoter-containing composition was spray-applied uniformly to the inner surface of the tubular container in an area of 7 to 40 mm from the opening of the tubular container.
- Example 32 A vacuum blood collection tube was obtained in the same manner as in Example 4 except that the blood coagulation promoter-containing composition was spray-applied uniformly to the inner surface of the tubular container in a region 7 to 50 mm from the opening of the tubular container.
- Example 3 A vacuum blood collection tube was obtained in the same manner as in Example 1 except that the type of the antifoaming agent and the blending amount thereof were changed as shown in Table 1 below.
- Example 4 A vacuum blood collection tube was obtained in the same manner as in Example 1 except that the antifoaming agent and the blood coagulation promoter (B) were not used.
- Example 5 A vacuum blood collection tube was obtained in the same manner as in Example 24 except that the antifoaming agent was not used.
- Example 6 A vacuum blood collection tube was obtained in the same manner as in Example 24 except that the antifoaming agent and the blood coagulation promoter (B) were not used.
- Example 7 A vacuum blood collection tube was obtained in the same manner as in Example 1 except that no antifoam was used.
- the blood clotting time was evaluated by measuring the time from when the blood was aspirated until the blood coagulation was confirmed visually. Furthermore, in each obtained vacuum blood collection tube, the presence or absence of peeling of the blood coagulation promoter-containing composition (drug) and the antifoaming agent-containing composition (drug) from the inner surface of the tubular container was evaluated. In addition, the presence or absence of suspended matters on the upper surface of the serum after centrifugation was evaluated.
- the vacuum blood collection tubes of Comparative Examples 1 to 3 to which 0.25 mg / mL of antifoam was added per 1 mL of blood had excellent antifoaming effects, but the antifoaming agent concentration was high and a large amount of the antifoaming agent was added to the upper surface of the serum after centrifugation Floating material was seen. From the above results, the amount of the antifoaming agent is more preferably 3 ⁇ 10 ⁇ 3 to 0.11 mg per 1 mL of collected blood.
- Example 28 In the vacuum blood collection tube of Example 28 in which 5 mg of water-soluble binder was added to 1 mL of blood to the antifoaming agent-containing composition, the elution rate of the blood coagulation accelerator was slow, so the coagulation time was long and the test value could be affected There is. From the above results, it is preferable that a water-soluble binder is added to the antifoaming agent-containing composition, and the amount of the water-soluble binder in the antifoaming agent-containing composition is 1 ⁇ 10 ⁇ 4 per 1 mL of collected blood. ⁇ 2 mg is preferable, and 1 ⁇ 10 ⁇ 3 to 1 mg is more preferable.
- the amount of the blood coagulation promoter (A) is preferably 0.5 to 50 units, more preferably 1 to 20 units, per 1 mL of collected blood.
- the accommodation position of the blood coagulation promoter-containing composition 4 is preferably within a region of 7 mm to 50 mm, more preferably within a region of 7 mm to 40 mm, most preferably within a region of 7 mm to 30 mm from the opening of the tubular container 2. .
- the blood coagulation promoter (A) is present at a position not in direct contact with the blood flow after blood collection in order to suppress the occurrence frequency of foam clots. Moreover, since the blood coagulation time (B) can be shortened and uniform coagulation can be achieved by adding the blood coagulation promoter (B), the blood coagulation promoter (B) is preferably contained in the blood collection container.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
Description
血液凝固促進剤(B):シリカ(UNIMIN SPECIALTY MINERAL社製)
消泡剤:
ポリオキシプロピレングリセリルエーテル(アデカポリエーテルG-4000、アデカ社製)
ポリ(オキシエチレン・オキシプロピレン)グリセリルエーテル(アデカポリエーテルAM-502、アデカ社製)
ポリオキシプロピレンエーテル(アデカポリエーテルP-3000、アデカ社製)
水溶性バインダー:ポリビニルピロリドン(PVP-K30、和光純薬社製)
管状容器:ポリエチレンテレフタレート製管状容器(内容積7.8mL、内径10.8mm×長さ100mm、積水化学工業社製)
血清分離剤:チクソトロピー性分離剤(積水化学工業社製)
栓体:ブチルゴム製栓体
上記管状容器の底部に血清分離剤としてのチクソトロピー性分離剤を0.8mL充填した。
消泡剤の種類及びその配合量を下記の表1に示すように代えたこと以外は実施例1と同様にして、真空採血管を得た。
上記消泡剤含有組成物における水溶性バインダーの配合量を下記の表1に示すように代えたこと以外は実施例4と同様にして、真空採血管を得た。
血液凝固促進剤(A)の配合量を下記の表1に示すように代えたこと以外は実施例4と同様にして、真空採血管を得た。
上記血液凝固促進剤含有組成物を管状容器の内面の全面に均一にスプレー塗布したこと以外は、実施例4と同様にして、真空採血管を得た。
消泡剤の種類を下記の表1に示すように代えたこと以外は実施例24と同様にして、真空採血管を得た。
上記消泡剤含有組成物に水溶性バインダーを添加しなかったこと以外は実施例4と同様にして、真空採血管を得た。
上記消泡剤含有組成物における水溶性バインダーの配合量を下記の表1に示すように代えたこと以外は実施例4と同様にして、真空採血管を得た。
血液凝固促進剤(A)の配合量を下記の表1に示すように代えたこと以外は実施例4と同様にして、真空採血管を得た。
上記血液凝固促進剤含有組成物を、管状容器の開口から7~40mmの領域において、管状容器の内面に均一にスプレー塗布したこと以外は実施例4と同様にして、真空採血管を得た。
上記血液凝固促進剤含有組成物を、管状容器の開口から7~50mmの領域において、管状容器の内面に均一にスプレー塗布したこと以外は実施例4と同様にして、真空採血管を得た。
消泡剤の種類及びその配合量を下記の表1に示すように代えたこと以外は実施例1と同様にして、真空採血管を得た。
消泡剤及び血液凝固促進剤(B)を用いなかったこと以外は実施例1と同様にして、真空採血管を得た。
消泡剤を用いなかったこと以外は実施例24と同様にして、真空採血管を得た。
消泡剤及び血液凝固促進剤(B)を用いなかったこと以外は実施例24と同様にして、真空採血管を得た。
消泡剤を用いなかったこと以外は実施例1と同様にして、真空採血管を得た。
各真空採血管の栓体を上方に向けた状態で、管状容器内にヒト新鮮血液を真空吸引した。しかる後、真空採血管を5秒かけて5回転倒混和し、5分間静置した。次に、遠心分離を行い、各30個の評価サンプルについて泡状の血餅の発生頻度及び凝固不良により発生するフィブリン析出の発生頻度(遅延フィブリン)を評価した。また、各真空採血管に5%BSA(ウシ血清アルブミン)溶液を吸引した後、5秒後の気泡の高さを測定し、気泡残存量を評価した。
、消泡効果に優れていたが、消泡剤濃度が高く、遠心分離後の血清上面に多量の浮遊物が見られた。以上の結果から、消泡剤の量は、採取される血液1mLあたり、3×10-3~0.11mgがより好ましい。
2…管状容器
2a…開口
2b…底部
2c…内壁面
3…栓体
3a…大径部
3b…小径部
4…血液凝固促進剤含有組成物
5…消泡剤含有組成物
6…血清分離剤
Claims (12)
- 血液凝固促進剤と、ポリオキシアルキレン又はその誘導体である消泡剤とが収容されており、
前記消泡剤の量が、血液採取容器内に採取される血液1mLあたり2.0×10-3~0.2mgの範囲とされていることを特徴とする、血液採取容器。 - 水溶性バインダーがさらに収容されている、請求項1に記載の血液採取容器。
- 前記水溶性バインダーが、ポリビニルアルコール、ポリビニルピロリドン、アクリル酸系共重合体及びポリオキシアルキレンブロック共重合体からなる群から選ばれた少なくとも1種である、請求項2に記載の血液採取容器。
- 血液採取容器内に採取される血液の液面よりも上方の第1の高さ位置から下方の第2の高さ位置に至るように、前記消泡剤が配置されている、請求項1~3のいずれか1項に記載の血液採取容器。
- 一端に開口を有する管状容器と、該開口に気密的に取付けられた栓体とを備える、請求項1~4のいずれか1項に記載の血液採取容器。
- 前記管状容器の内面の略全面に、前記消泡剤が付与されている、請求項5に記載の血液採取容器。
- 前記血液凝固促進剤が、セリンプロテアーゼを含む、請求項1~6のいずれか1項に記載の血液採取容器。
- 前記セリンプロテアーゼが、血液採取容器の内面にスプレー塗布されている、請求項7に記載の血液採取容器。
- 前記血液凝固促進剤が、吸着性無機物質を含む、請求項1~8のいずれか1項に記載の血液採取容器。
- 血液採取容器内に採取される血液の液面よりも上方の第1の高さ位置から下方の第2の高さ位置に至るように、前記吸着性無機物質が配置されている、請求項9に記載の血液採取容器。
- 前記管状容器の内面の略全面に、前記吸着性無機物質が付与されている、請求項9または10に記載の血液採取容器。
- 血液採取容器内が減圧されて真空採血管とされている、請求項1~11のいずれか1項に記載の血液採取容器。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009801331051A CN102132140B (zh) | 2008-08-28 | 2009-08-27 | 血液采集容器 |
CA2734711A CA2734711C (en) | 2008-08-28 | 2009-08-27 | Blood collection container |
JP2009552947A JP4521840B2 (ja) | 2008-08-28 | 2009-08-27 | 血液採取容器 |
EP09809975.7A EP2320208B1 (en) | 2008-08-28 | 2009-08-27 | Blood collection container |
US13/033,120 US8795957B2 (en) | 2008-08-28 | 2011-02-23 | Blood collection container |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008220029 | 2008-08-28 | ||
JP2008-220029 | 2008-08-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/033,120 Continuation US8795957B2 (en) | 2008-08-28 | 2011-02-23 | Blood collection container |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010024325A1 true WO2010024325A1 (ja) | 2010-03-04 |
Family
ID=41721491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/064947 WO2010024325A1 (ja) | 2008-08-28 | 2009-08-27 | 血液採取容器 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8795957B2 (ja) |
EP (1) | EP2320208B1 (ja) |
JP (1) | JP4521840B2 (ja) |
CN (1) | CN102132140B (ja) |
CA (1) | CA2734711C (ja) |
WO (1) | WO2010024325A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017075960A (ja) * | 2011-07-05 | 2017-04-20 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | 凝固制御剤およびそれを含む装置 |
CN107870246A (zh) * | 2010-09-20 | 2018-04-03 | Q-塞拉有限公司 | 血清制备 |
JP2020020639A (ja) * | 2018-07-31 | 2020-02-06 | デンカ生研株式会社 | 補体価測定用試薬及び補体価測定用試薬に生じる泡沫の消去方法 |
WO2021124847A1 (ja) | 2019-12-18 | 2021-06-24 | 積水メディカル株式会社 | 血液採取容器 |
KR20220115916A (ko) | 2019-12-18 | 2022-08-19 | 세키스이 메디칼 가부시키가이샤 | 혈액 채취 용기 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105683353A (zh) * | 2013-09-30 | 2016-06-15 | 积水医疗株式会社 | 循环肿瘤细胞浓缩分离设备及循环肿瘤细胞的浓缩分离方法 |
HUE044260T2 (hu) * | 2014-06-01 | 2019-10-28 | Debiopharm Int Sa | Mintagyûjtõ és feldolgozó eszköz |
JP6851946B2 (ja) * | 2016-10-07 | 2021-03-31 | アークレイ株式会社 | プラズマ分光分析方法、及び非ターゲットに由来するプラズマ発光の抑制剤 |
EP3918992A4 (en) * | 2019-02-01 | 2022-10-19 | Sekisui Medical Co., Ltd. | AGING PREVENTING AGENT AND BLOOD COLLECTION CONTAINERS |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001269328A (ja) | 2000-03-27 | 2001-10-02 | Sekisui Chem Co Ltd | 採血管 |
JP2002267660A (ja) * | 2001-03-09 | 2002-09-18 | Sekisui Chem Co Ltd | 血液検査用容器 |
JP2002323488A (ja) | 1996-11-21 | 2002-11-08 | Sekisui Chem Co Ltd | 血液凝固促進剤及び血液検査用容器 |
JP2004049894A (ja) * | 2002-05-29 | 2004-02-19 | Sekisui Chem Co Ltd | 血液検査用有底管、血液検査用有底管の栓体及び血液検査用容器 |
JP2007248175A (ja) * | 2006-03-15 | 2007-09-27 | Sekisui Chem Co Ltd | 血液検査用容器 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6368138A (ja) * | 1986-09-11 | 1988-03-28 | 株式会社ニツシヨ− | 真空採血管 |
US5257633A (en) * | 1992-06-23 | 1993-11-02 | Becton, Dickinson And Company | Surface modified blood collection tubes |
JP3247070B2 (ja) | 1997-03-21 | 2002-01-15 | 積水化学工業株式会社 | 血液検査用容器及びその製造方法 |
US6686204B2 (en) * | 2001-08-27 | 2004-02-03 | Becton, Dickinson & Company | Collection device |
TR201907217T4 (tr) | 2002-05-29 | 2019-06-21 | Sekisui Chemical Co Ltd | Tabanlı kan tahlili tüpü, kan tahlili tüpü için tıkaç ve kan tahlili kabı. |
JP2004148194A (ja) * | 2002-10-30 | 2004-05-27 | Komatsu Denshi Kk | 振とう装置 |
KR100827297B1 (ko) | 2005-03-17 | 2008-05-06 | 세키스이가가쿠 고교가부시키가이샤 | 혈액응고 촉진제 및 혈액 검사용 용기 |
-
2009
- 2009-08-27 CN CN2009801331051A patent/CN102132140B/zh active Active
- 2009-08-27 EP EP09809975.7A patent/EP2320208B1/en active Active
- 2009-08-27 WO PCT/JP2009/064947 patent/WO2010024325A1/ja active Application Filing
- 2009-08-27 CA CA2734711A patent/CA2734711C/en active Active
- 2009-08-27 JP JP2009552947A patent/JP4521840B2/ja active Active
-
2011
- 2011-02-23 US US13/033,120 patent/US8795957B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002323488A (ja) | 1996-11-21 | 2002-11-08 | Sekisui Chem Co Ltd | 血液凝固促進剤及び血液検査用容器 |
JP2001269328A (ja) | 2000-03-27 | 2001-10-02 | Sekisui Chem Co Ltd | 採血管 |
JP2002267660A (ja) * | 2001-03-09 | 2002-09-18 | Sekisui Chem Co Ltd | 血液検査用容器 |
JP2004049894A (ja) * | 2002-05-29 | 2004-02-19 | Sekisui Chem Co Ltd | 血液検査用有底管、血液検査用有底管の栓体及び血液検査用容器 |
JP2007248175A (ja) * | 2006-03-15 | 2007-09-27 | Sekisui Chem Co Ltd | 血液検査用容器 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2320208A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107870246A (zh) * | 2010-09-20 | 2018-04-03 | Q-塞拉有限公司 | 血清制备 |
CN107870246B (zh) * | 2010-09-20 | 2021-04-09 | Q-塞拉有限公司 | 血清制备 |
JP2017075960A (ja) * | 2011-07-05 | 2017-04-20 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | 凝固制御剤およびそれを含む装置 |
US9949473B2 (en) | 2011-07-05 | 2018-04-24 | Becton, Dickinson And Company | Coagulation controlling agents and devices comprising the same |
JP2020020639A (ja) * | 2018-07-31 | 2020-02-06 | デンカ生研株式会社 | 補体価測定用試薬及び補体価測定用試薬に生じる泡沫の消去方法 |
JP7082544B2 (ja) | 2018-07-31 | 2022-06-08 | デンカ株式会社 | 補体価測定用試薬及び補体価測定用試薬に生じる泡沫の消去方法 |
WO2021124847A1 (ja) | 2019-12-18 | 2021-06-24 | 積水メディカル株式会社 | 血液採取容器 |
KR20220115916A (ko) | 2019-12-18 | 2022-08-19 | 세키스이 메디칼 가부시키가이샤 | 혈액 채취 용기 |
Also Published As
Publication number | Publication date |
---|---|
CA2734711A1 (en) | 2010-03-04 |
CA2734711C (en) | 2012-10-30 |
CN102132140A (zh) | 2011-07-20 |
EP2320208A1 (en) | 2011-05-11 |
US8795957B2 (en) | 2014-08-05 |
EP2320208A4 (en) | 2011-11-16 |
EP2320208B1 (en) | 2013-10-16 |
US20110144536A1 (en) | 2011-06-16 |
JP4521840B2 (ja) | 2010-08-11 |
CN102132140B (zh) | 2013-06-12 |
JPWO2010024325A1 (ja) | 2012-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4521840B2 (ja) | 血液採取容器 | |
EP0875756B1 (en) | Additive preparation and method of use thereof | |
JP2009101175A (ja) | 血液接触面を有する医療用品 | |
EP1215494B1 (en) | Method of preparing a blood collection device and an additive composition | |
JP4219361B2 (ja) | 血液凝固促進剤及び採血管 | |
EP0902289B1 (en) | Additive formulation comprising heparin-specific glucanase and use thereof | |
JP4852479B2 (ja) | 血液凝固促進剤含有組成物及び血液検査用容器 | |
KR100981496B1 (ko) | 혈액 검사용 유저관, 혈액 검사용 유저관의 마개 및 혈액검사용 용기 | |
JP4504506B2 (ja) | 血液検査用容器 | |
JP3851442B2 (ja) | 血液凝固促進剤及び血液検査用容器 | |
JP3887190B2 (ja) | 血液検査用容器及びその製造方法 | |
JP3247070B2 (ja) | 血液検査用容器及びその製造方法 | |
JP2000175890A (ja) | 液体分離容器の製造方法 | |
US20100248329A1 (en) | Blood coagulation promoter and blood collection tube | |
US20230050815A1 (en) | Blood collection container | |
WO2009110488A1 (ja) | 採血管 | |
WO2021124847A1 (ja) | 血液採取容器 | |
JP3836446B2 (ja) | 血液検査用有底管、血液検査用有底管の栓体及び血液検査用容器 | |
JPH02305554A (ja) | 液体試料微量採取管 | |
JP2002345463A (ja) | 核酸吸着バッファ及び核酸精製方法 | |
JP2024074252A (ja) | 血液採取容器 | |
AU2002300487B2 (en) | Additive preparation and method of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980133105.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009552947 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09809975 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2734711 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009809975 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |